Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked in traditional channels.
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling
Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to meet outsized demand.
Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried
CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a “financial impact” on the pharma giant.
FDA adds new warning to weight loss drugs including Wegovy
The U.S. Food and Drug Administration has added a new warning to drugs including Ozempic and Wegovy, cautioning that patients taking the drugs may be at a higher risk of inhaling gastric contents into their lungs while under anesthesia.
FDA approves a new weight loss drug, Zepbound from Eli Lilly
The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
FDA adds new warning to popular weight loss drugs
The Food and Drug Administration has updated labels for popular weight loss drugs like Ozempic and Wegovy. President-elect Donald Trump has sent mixed signals for years on whether he would fire or demote Jerome Powell.
Hosted on MSN2h
Novo Stock Has Been Slammed. How a New Weight-Loss Drug Could Boost Shares by 10%.
The company predicts the combination can help patients lose about 25% of their body weight, more than approved drugs Wegovy ...
24/7 Wall St8h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Eli Lilly has received approval to start selling its weight loss drug, Mounjaro, in Hong Kong as early as the end of this ...
1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock
Conditions are getting a bit more challenging for the drugmaker.
Gradual dosing of Lilly Alzheimer's drug cuts brain-swelling risk, study finds
Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...
STAT19h
Risk of aspiration during surgery added to GLP-1 drug labels
The drugs whose labels were updated include Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro. The agency said, ...
BioPharma Dive12d
Lilly shares fall as obesity drug sales miss forecasts
Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...
The Associated Press - Business News on MSN12d
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
STAT13d
Eli Lilly says modified dosing of its Alzheimer’s drug may be safer
A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among ...
Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.
Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...
FiercePharma3d
While Novo and Lilly's market value declined in Q3, BMS, Gilead and Sanofi surged: GlobalData
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...